Pollen allergen sublingual tablet and preparation method therefor
Sublingual tablets prepared using vacuum freeze-drying technology solve the stability and disintegration problems of existing sublingual drops and sprays, achieving rapid disintegration and high compliance in sublingual pollen allergen treatment, suitable for rapid treatment and diagnosis of pollen allergies.
Patent Information
- Application Number
- PCT/CN2026/097376
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-15
- Filing Date
- 2026-05-15
- Publication Date
- 2026-11-19
AI Technical Summary
Existing sublingual drops or sprays for treating pollen allergies suffer from poor drug stability, insufficient dosage accuracy, unpleasant taste, and slow disintegration. Traditional sublingual tablets are dense and disintegrate slowly, resulting in poor patient compliance.
Sublingual tablets containing pollen allergen, gelatin, and mannitol were prepared using vacuum freeze-drying technology. A loosely porous drug-loaded framework was prepared by pre-freezing, sublimation drying, and desorption drying to ensure rapid disintegration and high biostability.
It achieves rapid disintegration of sublingual tablets (less than 2 seconds), eliminates the need for water administration, improves patient compliance, is suitable for the elderly, children, and patients with swallowing difficulties, and is easy to store and carry, with good dosage accuracy.
Smart Images

Figure PCTCN2026097376-FTAPPB-I100001 
Figure PCTCN2026097376-FTAPPB-I100002 
Figure PCTCN2026097376-FTAPPB-I100003
Abstract
Description
A pollen allergen sublingual tablet and its preparation method Technical Field
[0001] This disclosure relates to the field of pharmaceutical preparations, specifically to a pollen allergen sublingual tablet and its preparation method. Background Technology
[0002] Allergic diseases are a series of illnesses caused by a disruption of the immune system after exposure to allergens. These diseases can affect multiple systems throughout the body, causing damage to multiple systems and organs, including allergic asthma, allergic rhinitis, allergic conjunctivitis, urticaria, and atopic dermatitis. Globally, over 30% of the population is affected by allergic diseases, while the incidence rate in China is as high as 27%, and this rate has been rising in recent years. Allergic diseases significantly reduce patients' quality of life; their recurrent nature increases stress, leads to depression, and can even be life-threatening, thus creating a significant socioeconomic burden.
[0003] Among numerous allergens, pollen is one of the major allergens. Large amounts of pollen from allergenic plants are dispersed in the air, and inhalation can trigger a series of allergic reactions such as allergic rhinitis, bronchial asthma, and dermatitis. These allergic diseases caused by pollen allergy are collectively known as hay fever. With the increasing urbanization and expansion of plant cultivation areas, pollen allergens have also increased, and pollen allergy has become a seasonal epidemic with a relatively high incidence rate. Research on pollen allergy began in my country in the 1960s. Experts and scholars in Beijing confirmed that the allergenic pollen in my country differs from that found in foreign studies, clearly identifying Artemisia pollen as the most prevalent allergenic pollen causing pollen allergies in my country.
[0004] A survey of airborne allergenic pollen in China shows that Artemisia pollen is most abundant in many regions during summer and autumn. Recent surveys indicate that Artemisia pollen remains the most important allergenic pollen in northern my country during summer and autumn, with an average allergy rate of 28.6% nationwide, 33.6% in Northeast China, and 58.2% in Northwest China. The dispersal period of Artemisia pollen generally begins at the end of July and ends in October. There are four main types of Artemisia pollen that cause allergies in my country: Artemisia macrophylla pollen, Artemisia annua pollen, Artemisia argyi pollen, and Artemisia sphaerocephala pollen. An early study of 215,210 allergen-specific IgE tests conducted in Beijing from 2008 to 2010 showed that among 104 inhaled allergen species, Artemisia pollen had the highest positive rate at 64.4%.
[0005] Currently, specific immunotherapy is one of the main treatments for allergic diseases. It involves repeatedly exposing patients to gradually increasing doses of allergen extracts to induce a specific immune response, enhancing the immune system's tolerance to the allergen and thus controlling or alleviating allergy symptoms. Allergen-specific immunotherapy is usually administered subcutaneously (SCIT) to induce tolerance to the allergen; however, its application is limited due to significant adverse reactions and the potential for anaphylactic shock. Recently, sublingual immunotherapy (SLIT), administered sublingually, has garnered considerable clinical attention. Compared to SCIT, SLIT can be taken at home, offering greater convenience and higher compliance. Clinical studies have also confirmed its safety and effectiveness. Furthermore, SLIT can significantly reduce clinical costs, alleviating the burden on patients and society.
[0006] Currently available medications for treating pollen allergies are mostly allergen injections administered subcutaneously. Sublingual medications are less common, and those that are available are primarily liquid sublingual drops or sprays; sublingual tablets without allergens are not available. Sublingual drops or sprays have numerous drawbacks, including poor drug stability and storage conditions, inconsistent dosage accuracy and efficacy, and unpleasant taste. Furthermore, traditionally compressed sublingual tablets are dense and disintegrate slowly, requiring 15 seconds or more, and cause a noticeable foreign body sensation during administration, leading to poor patient compliance. Summary of the Invention
[0007] On one hand, this disclosure provides a method for preparing a sublingual tablet, the sublingual tablet comprising pollen allergen, gelatin, and mannitol. The preparation method includes sequentially pre-freezing, sublimation drying, and desorption drying of a lyophilization composition comprising pollen allergen, gelatin, and mannitol; wherein, relative to the lyophilization composition, the amount of gelatin is 3% to 10% (w / v), and the amount of mannitol is 3% to 10% (w / v); the pre-freezing temperature is -60℃ to -120℃, and the time is 2.5 to 30 min; the sublimation drying temperature is -5℃ to -30℃, and the time is 3 to 7 h.
[0008] According to this disclosure, the pollen allergens may be derived from one or more of the following: weed pollen (e.g., Artemisia pollen, Kochia pollen, Ragweed pollen, Humulus pollen, Xanthium pollen, etc.), pasture pollen (e.g., Setaria pollen, Tigrass pollen, Bermuda grass pollen, etc.), and tree pollen (e.g., Juniperus pollen, Ash pollen, Birch pollen, Platanus pollen (e.g., Platanus sylvestris, Platanus triloba, Platanus terrestris) pollen, Juniperus chinensis pollen, Populus pollen, Cryptomeria japonica pollen, Elm pollen, and Willow pollen).
[0009] In some preferred embodiments, the pollen allergen is an Artemisia pollen allergen. Examples of Artemisia species include one or more of Artemisia sieversiana, Artemisia annua, Artemisia vulgaris, Artemisia desertorum, Artemisia ordosica, and Artemisia stelleriana.
[0010] According to this disclosure, the pollen allergen can be any plant-derived pollen allergen that can be used to prepare sublingual tablets, and there are no particular restrictions on its preparation method, etc.
[0011] The aforementioned pollen allergens can be detected by SDS-PAGE and Western blotting. For example, the allergenic protein distribution of Artemisia annua pollen allergens is 10–20 kDa, 25–35 kDa, 40–55 kDa, and 65–75 kDa; that of Artemisia argyi pollen allergens is 10–20 kDa, 25–40 kDa, and 55–75 kDa; that of Artemisia argyi pollen allergens is 10–20 kDa, 25–35 kDa, and 45–75 kDa; and that of Artemisia sphaerocephala pollen allergens is 10–15 kDa, 25–40 kDa, and 65–75 kDa. Considering improving the properties of sublingual tablets, pollen allergen extracts can be used as pollen allergens for preparing sublingual tablets, preferably those containing the aforementioned corresponding allergenic proteins.
[0012] In some specific embodiments, pollen allergen extracts can be prepared, for example, by the following method: Pollen (g) and acetone (mL) are stirred and defatted at a weight-to-volume ratio (w / v) of 1:1 to 5. The mixture is allowed to stand and separate into layers. The clarity of the upper liquid is observed. Defatting is repeated until the upper liquid is clear. The defatted pollen is then evenly spread and dried at room temperature to obtain defatted and purified pollen raw material. The defatted and purified pollen raw material is added to a 10-100 mM phosphate extraction solution with pH 7.9-8.2 at a weight-to-volume ratio (w / v) of 1:10 to 50, and extracted by stirring at 2°C to 8°C for at least 12 hours. After extraction, the mixture is centrifuged at 2°C to 8°C at a centrifugal force of 8000-12000 g for 15-20 minutes, and the supernatant is collected. The supernatant was filtered sequentially through filter membranes (e.g., 0.45 μm and 0.22 μm), then concentrated by ultrafiltration (e.g., 3 kD), and freeze-dried to obtain the pollen allergen extract.
[0013] In some specific embodiments, the pollen allergens are selected as needed, and there is no particular limitation on the types of pollen allergens. For example, 1 to 20 types or 4 to 10 types can be used, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 types. When multiple pollen allergens are included, the ratio of each pollen allergen can be appropriately determined. For example, the ratio of any two pollen allergens can be 1:0.1 to 10 or 1:0.5 to 2, such as 1:1.
[0014] In some specific embodiments, the Artemisia pollen allergens include one or more selected from Artemisia macrocarpa pollen allergens, Artemisia annua pollen allergens, Artemisia argyi pollen allergens, and Artemisia sphaeroides pollen allergens.
[0015] In some specific embodiments, the protein content ratio (by weight) of Artemisia pollen allergens, including Artemisia macrocarpa pollen allergen, Artemisia annua pollen allergen, Artemisia argyi pollen allergen, and Artemisia sphaeroides pollen allergen, is 1:(0.1-10):(0.1-10):(0.1-10), preferably 1:(0.5-2):(0.5-2):(0.5-2), for example, 1:1:1:1.
[0016] According to this disclosure, any gelatin used in the preparation of sublingual tablets can be used, such as fish gelatin (e.g., cold-water fish gelatin, warm-water fish gelatin), pork gelatin, bovine bone gelatin, etc. From the perspective of improving the properties of sublingual tablets, fish gelatin is preferred, cold-water fish gelatin is more preferred, and deep-sea cold-water fish gelatin is even more preferred, such as salmon gelatin, cod gelatin, yellow croaker gelatin, and tuna gelatin. As the above-mentioned gelatin, fish skin gelatin, i.e., gelatin made from fish skin, is preferred.
[0017] In some specific embodiments, the amount of gelatin used relative to the freeze-drying composition is 3% to 10% (w / v), preferably 4% to 7% (w / v). Specifically, the amount of gelatin used relative to the freeze-drying composition can be, for example, 3% (w / v), 4% (w / v), 5% (w / v), 6% (w / v), 7% (w / v), 8% (w / v), 9% (w / v), or 10% (w / v).
[0018] In some specific embodiments, the amount of mannitol used relative to the lyophilization composition is 3% to 10% (w / v), preferably 5% to 7% (w / v). Specifically, the amount of mannitol used relative to the lyophilization composition can be, for example, 3% (w / v), 4% (w / v), 5% (w / v), 6% (w / v), 7% (w / v), 8% (w / v), 9% (w / v), or 10% (w / v).
[0019] In some specific embodiments, gelatin and mannitol can be prepared into an excipient solution according to the required amount. For example, they can be mixed in a water bath at about 40°C until the excipients are completely dissolved without any clumping or sedimentation, and then stored at room temperature for later use.
[0020] In some specific embodiments, the pollen allergen content relative to the lyophilization composition is 0.01–2.0 mg / mL, preferably 0.1–2 mg / mL. Preferably, the pollen allergen biopotency is 50,000–200,000 AU / mL. Specifically, the pollen allergen content relative to the lyophilization composition can be, for example, 0.01 mg, 0.025 mg, 0.05 mg, 0.075 mg, 0.1 mg, 0.2 mg, 0.25 mg, 0.3 mg, 0.4 mg, 0.5 mg, 0.6 mg, 0.7 mg, 0.8 mg, 0.9 mg, 1 mg, 1.2 mg, 1.5 mg, 1.7 mg, or 2 mg.
[0021] In some specific embodiments, the preparation method includes adjusting the pH of the lyophilization composition to 6.5–7.5, preferably 6.5–7.2, and more preferably 6.8–6.9 before pre-freezing. Preferably, the pH of the lyophilization composition is adjusted using sodium hydroxide or a solution thereof. The concentration of the sodium hydroxide solution used can be, for example, 0.001–3 mol / L, preferably 0.005–0.02 mol / L.
[0022] In some specific embodiments, the preparation method further includes a step of sterilizing the freeze-drying composition before pre-freezing, for example, by using a 0.22 μm polyethersulfone membrane for sterilization filtration.
[0023] In some specific embodiments, the preparation method further includes: blister loading of the lyophilization composition before pre-freezing. The loading method is as follows: remove the blister pack, check whether the bottom of the blister pack is flat, use a tool to flatten the bottom of the blister pack so that each blister pack can contact the partition; add the well mixed material solution into the blister pack using the reverse pipetting method.
[0024] In some specific embodiments, the pre-freezing temperature is -60℃ to -120℃, preferably -80℃ to -120℃. Specifically, the pre-freezing temperature can be, for example, -120℃, -110℃, -100℃, -90℃, -80℃, -70℃, or -60℃. In some specific embodiments, the pre-freezing time is 2 to 30 minutes, preferably 2.5 to 30 minutes. Specifically, the pre-freezing time can be, for example, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 15 minutes, 20 minutes, or 30 minutes.
[0025] In some specific embodiments, the sublimation drying temperature is -5℃ to -30℃, preferably -15℃ to -25℃. Specifically, the sublimation drying temperature can be, for example, -30℃, -25℃, -20℃, -15℃, -10℃, or -5℃. In some specific embodiments, the sublimation drying time is 3 to 7 hours, preferably 5 to 7 hours. Specifically, the sublimation drying time can be, for example, 3 hours, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 5.5 hours, 6 hours, 6.5 hours, or 7 hours. In some specific embodiments, the vacuum degree of the sublimation drying is 15 to 25 Pa.
[0026] In some specific embodiments, the temperature for the desorption drying is 20℃ to 30℃, preferably 24℃ to 26℃, for example, 25℃. Specifically, the temperature for the desorption drying can be, for example, 20℃, 21℃, 22℃, 23℃, 24℃, 25℃, 26℃, 27℃, 28℃, 29℃, or 30℃. In some specific embodiments, the time for the desorption drying is 1 to 3 hours, preferably 2.5 hours. Specifically, the time for the desorption drying can be, for example, 1 hour, 1.5 hours, 2 hours, 2.5 hours, or 3 hours. In some specific embodiments, the vacuum degree for the sublimation drying is 1 to 10 Pa.
[0027] In some specific implementations, pre-freezing can be carried out using, for example, an ultra-low temperature freezer, while sublimation drying and desorption drying are carried out using a freeze dryer.
[0028] In some specific embodiments, the temperature change rate between the pre-freezing and the sublimation drying and / or between the sublimation drying and the desorption drying can be, for example, 0.5℃ / min to 2℃ / min, such as 0.5℃ / min, 1℃ / min, 1.5℃ / min or 2℃ / min, preferably 0.9℃ / min to 1.1℃ / min.
[0029] The method for preparing sublingual tablets disclosed herein, and the freeze-drying curves are shown in Table 1 below.
[0030] Table 1
[0031] On the other hand, this disclosure provides a sublingual tablet comprising the Artemisia pollen allergen, gelatin, and mannitol as described above. Preferably, the sublingual tablet is prepared by the method described above.
[0032] In some specific embodiments, the sublingual tablet is in single-dose form, wherein the total protein content (i.e., total active ingredient) of Artemisia pollen allergen in the sublingual tablet is 4–800 μg / tablet, preferably 40–400 μg / tablet. For example, the sublingual tablet can be in single-dose form with a total protein content of Artemisia pollen allergen of 4 μg, 5 μg, 10 μg, 50 μg, 100 μg, 200 μg, 300 μg, 400 μg, 500 μg, 600 μg, 700 μg, or 800 μg. The biopotency of the pollen allergen in the sublingual tablet is 20,000–80,000 AU / tablet. Furthermore, the filling volume of the sublingual tablet before lyophilization is 200–800 μL / tablet, preferably 300–600 μL / tablet, and more preferably 400 μL / tablet.
[0033] In some specific embodiments, the sublingual tablet is a rapidly disintegrating sublingual tablet. Preferably, the disintegration time of the sublingual tablet is within 20 seconds, more preferably within 10 seconds, more preferably within 5 seconds, for example, less than 2 seconds.
[0034] On the other hand, this disclosure provides the use of the sublingual tablets described above in the preparation of medicines or reagents for treating and / or preventing allergic rhinitis, allergic conjunctivitis or allergic asthma caused by Artemisia pollen or for diagnosing allergies.
[0035] On the other hand, this disclosure provides a method for treating and / or preventing allergic rhinitis, allergic conjunctivitis or allergic asthma caused by Artemisia pollen, comprising administering a sublingual tablet as described above to a subject in need.
[0036] On the other hand, this disclosure provides a method for diagnosing allergies, which includes administering a sublingual tablet as described above to a subject in need.
[0037] On the other hand, this disclosure provides sublingual tablets as described above for the treatment and / or prevention of allergic rhinitis, allergic conjunctivitis or allergic asthma caused by Artemisia pollen, or for the diagnosis of allergies.
[0038] The sublingual tablets disclosed herein have advantages over sublingual drops or sprays, including lower water content, stronger biological stability, easier storage, portability, convenience of administration, and accurate dosage. They disintegrate rapidly in the mouth via saliva alone, eliminating the need for water and improving patient compliance. Their active ingredients are rapidly absorbed directly through the oral mucosa, avoiding the first-pass effect in the liver, making them particularly suitable for the elderly, children, and patients with swallowing difficulties.
[0039] The sublingual tablets disclosed herein are prepared using vacuum freeze-drying technology. Compared with traditional methods, they have a drug-carrying skeleton with a loose porous structure, high porosity, rapid disintegration (less than 2 seconds), no need for water administration, and can be stored for a long time. They also significantly reduce the foreign body sensation when taken orally, improve patient compliance, and are more suitable for children. Attached Figure Description
[0040] This disclosure can be more fully understood with reference to the following figures.
[0041] Figure 1 shows the SDS-PAGE results of four Artemisia pollen allergen extract stock solutions. A: Detection results of Artemisia macrocarpa pollen allergen extract, B: Detection results of Artemisia annua pollen allergen extract, C: Detection results of Artemisia argyi pollen allergen extract, D: Detection results of Artemisia serrata pollen allergen extract, M: Marker, Lane 1: Artemisia pollen allergen standard, Lane 2: Artemisia pollen allergen stock solution.
[0042] Figure 2 shows the Western blot results of four Artemisia pollen allergen extracts. M: Marker, Lane 1: Artemisia macrocarpa pollen allergen extract, Lane 2: Artemisia annua pollen allergen extract, Lane 3: Artemisia argyi pollen allergen extract, Lane 4: Artemisia sphaerocephala pollen allergen extract.
[0043] Figure 3 shows the finished product of the mixed Artemisia pollen sublingual tablets (Group 48, front and back).
[0044] Figure 4 shows the dose-response curve of the relative potency of the mixed Artemisia pollen sublingual tablets. Reference and Control are Artemisia pollen allergen standards (for sublingual tablets).
[0045] Figure 5 shows the histopathological examination results of a mouse model of Artemisia pollen allergy after sublingual treatment with mixed Artemisia pollen sublingual tablets. Detailed Implementation
[0046] The following description of this disclosure is merely intended to illustrate various embodiments of the disclosure. Therefore, the specific modifications discussed should not be construed as limiting the scope of this disclosure. It will be apparent to those skilled in the art that various equivalents, changes, and modifications can be made without departing from the scope of this disclosure, and it should be understood that these equivalent embodiments are included herein. All references cited herein, including publications, patents, and patent applications, are incorporated herein by reference in their entirety.
[0047] The term "deep-sea cold-water fish gelatin" as used in this article refers to gelatin prepared from the skin or scales of deep-sea cold-water fish. "Cold-water fish gelatin" refers to gelatin prepared from the skin or scales of cold-water fish. "Warm-water fish gelatin" refers to gelatin prepared from the skin or scales of warm-water fish. Deep-sea cold-water fish refers to fish that live in cold waters of the deep sea (below 100 meters) and thrive in temperatures below 10°C, such as Atlantic salmon and cod. Cold-water fish refers to fish that thrive in temperatures between 10°C and 20°C, such as rainbow trout. Warm-water fish refers to fish that thrive in temperatures between 20°C and 30°C, such as tilapia and grass carp.
[0048] For example, the following methods can be used to prepare fish gelatin: Add 0.5–2 mol / L NaOH solution at a weight-to-volume ratio (w / v) of 1:2–50, soak for at least 1 hour, stirring at room temperature. After soaking, rinse with distilled water until neutral, and blot dry with absorbent paper. Soak fish skin or scales in 0.02–0.1 M acetic acid solution at a weight-to-volume ratio (w / v) of 1:2–50 for at least 3 hours, then rinse with distilled water until neutral. Soak fish skin or scales in distilled water at a weight-to-volume ratio (w / v) of 1:2–50 at 45–55°C, stirring and extracting for at least 3 hours. After extraction, filter to remove impurities, and dry to obtain fish gelatin.
[0049] The quality control standards for Artemisia pollen allergens used in this article are as follows: The appearance is a white to brown solid; the protein composition spectrum should show a clear band at 26–30 kDa (SDS-PAGE method, Chinese Pharmacopoeia 2020 Edition, Part III, General Chapter 0541, Method 5; the protein composition spectrum should conform to the sensitizing component sizes published by the WHO / IUIS Allergen Nomenclature Sub-Committee); and the total protein content should be 0.400–0.600 mg / bottle (Bradford method, Chinese Pharmacopoeia 2020 Edition, Part III, General Chapter 0731).
[0050] In this disclosure, pollen allergen protein content is expressed by weight.
[0051] As used herein, the term "treatment" refers to the administration of an effective amount of a drug to a subject so that the subject experiences a reduction in at least one symptom of the disease or an improvement in the disease, for example, a beneficial or desired clinical outcome. For the purposes of this disclosure, a beneficial or desired clinical outcome includes, but is not limited to, the reduction of one or more symptoms, a decrease in the severity of the disease, stabilization of the disease state (i.e., no worsening), a delay or slowing of disease progression, an improvement or mitigation of the disease state, and remission (whether partial or complete), whether detectable or undetectable. Treatment may also mean an extension of survival compared to the expected survival without treatment. Therefore, those skilled in the art will recognize that treatment may improve the disease condition but may not be a complete cure. As used herein, treatment is "effective" when disease progression is reduced or stopped. "Treatment" may also mean an extension of survival compared to the expected survival without treatment. Patients requiring treatment include those already diagnosed with a condition to be treated, and those who may develop such a condition due to genetic susceptibility or other factors.
[0052] As used in this article, the term "prevention" may refer to complete protection from disease or to prevention of disease progression. For example, disease prevention may not mean the complete loss of any disease-related effects at any level, but may mean preventing disease symptoms from reaching a clinically significant or detectable level. Disease prevention may also mean preventing the disease from progressing to a later stage. As used in this article, "prevention" encompasses the treatment of diseases in mammals, particularly humans, including: (a) preventing the onset of disease or symptoms in susceptible individuals who have not yet been diagnosed with the disease; (b) suppressing disease, such as halting disease progression; or (c) alleviating disease, such as reducing disease-related symptoms.
[0053] As used herein, the term "diagnosis" refers to the process of identifying the presence and / or nature of a disease, symptom, or other physiological state in a subject based on its characteristics, signs, and symptoms. A diagnosis may include statements or conclusions relating to a disease, symptom, or other physiological state in a subject based on this process.
[0054] As used herein, the term "effective amount" or "therapeutic effective amount" refers to an amount of therapeutic agent (e.g., a sublingual tablet provided herein) sufficient to treat, diagnose, prevent, delay the onset of a given condition, disorder, or disease and / or associated symptoms, reduce and / or alleviate its severity and / or duration. These terms also cover the amount required to reduce, slow, or alleviate the progression or development of a given disease, reduce, slow, or alleviate the recurrence, development, or onset of a given disease, and / or enhance or strengthen the preventive or therapeutic effect of another therapy or serve as a bridge to another therapy. In some embodiments, "effective amount" as used herein may also refer to the amount of the therapeutic agent described herein (e.g., a sublingual tablet provided herein) required to achieve the specified result.
[0055] The terms "patient" and "subject" are used interchangeably and can mean any living organism that can be treated with the sublingual tablets of the present invention. Therefore, a subject can include, but is not limited to, any non-human mammal, primate, or human. In some embodiments, the subject is a mammal, such as a mouse, rat, other rodent, rabbit, dog, cat, pig, cow, sheep, horse, primate, or human. In some embodiments, the subject is an adult, child, or infant. In some embodiments, the subject is a human.
[0056] Example
[0057] To enable those skilled in the art to better understand the present disclosure, the technical solutions in the embodiments of the present disclosure will be clearly and completely described below. Obviously, the described embodiments are only some embodiments of the present disclosure, and not all embodiments.
[0058] Example 1: Preparation of extracts from four Artemisia species of pollen allergens
[0059] (1) Preparation of pollen allergens from four Artemisia species
[0060] For each of the four Artemisia species, Artemisia pollen (g) and acetone (mL) were stirred and defatted for 30 min at a weight-to-volume ratio (w / v), allowed to stand and separate into layers, and the clarity of the upper liquid was observed. The defatting was repeated until the upper liquid was clear, and then the defatted pollen was evenly spread out and dried at room temperature for more than 48 h.
[0061] The defatted and purified Artemisia pollen obtained above was added to 40mM phosphate extraction solution (pH 7.9–8.2) at a weight-to-volume ratio of 1:25 (w / v) and extracted by stirring at 2℃–8℃ for 24 h. After extraction, the mixture was centrifuged at 8000–12000g for 15–20 minutes at 2℃–8℃, and the supernatant was collected. The filtrate was filtered sequentially through 0.45μm and 0.22μm filter membranes, and then concentrated to 1 mg / mL by ultrafiltration using a 3KD ultrafiltration membrane. The extract was then freeze-dried to obtain the Artemisia pollen allergen extract.
[0062] (2) Determination of allergen protein content in pollen from four Artemisia species
[0063] Protein content was determined using the Bradford method with Coomassie Brilliant Blue assay at standard BSA concentrations of 500, 400, 300, 200, 100, and 50 μg / mL. Based on the theoretical concentration of the extract, the sample concentration was adjusted to the standard BSA detection range (50-500 μg / mL), and the adjustment factor was recorded. 15 μL of standard BSA solution and extract sample were added to each well of a 96-well microplate. 285 μL of 1× dye working solution (Applygen, P1510) was added, and the OD595 value was measured at 595 nm using a microplate reader. A standard protein curve was obtained by plotting the standard BSA concentrations (50–500 μg / mL) on the ordinate and the OD595 value on the abscissa. Based on the standard protein curve and the OD595 value of the extract sample, the adjusted sample protein concentration was calculated, and then multiplied by the adjustment factor to obtain the total protein concentration of the extract.
[0064] The concentrations of the four Artemisia genus pollen allergens were measured to be in the range of 1.0–1.2 mg / mL.
[0065] Example 2: Identification of allergen components and determination of total allergen activity in pollen from four Artemisia species
[0066] (1) Identification of total protein components of four Artemisia species pollen allergens by SDS-PAGE method
[0067] The reducing SDS-PAGE method was used, with a separating gel concentration of 4%–12%, and Coomassie brilliant blue staining was applied.
[0068] The experimental results are shown in Figure 1. Figure 1A shows the detection results of pollen allergen extracts from Artemisia annua, Figure 1B shows the detection results of pollen allergen extracts from Artemisia argyi, Figure 1C shows the detection results of pollen allergen extracts from Artemisia argyi, and Figure 1D shows the detection results of pollen allergen extracts from Artemisia serrata. M stands for Genstar M223-01 Marker. Lane 1 contains pollen allergen standards for each Artemisia genus (for sublingual tablets), and lane 2 contains pollen allergen extracts for each Artemisia genus.
[0069] The extract of Artemisia annua pollen allergen showed protein bands in the ranges of 10–20 kDa, 25–35 kDa, 40–55 kDa, and 65–75 kDa, which were consistent with the bands of the standard.
[0070] The extract of Artemisia annua pollen allergen showed protein bands in the ranges of 10–20 kDa, 25–40 kDa, and 55–75 kDa, which were consistent with the bands of the standard.
[0071] Artemisia pollen allergen extract showed protein bands in the ranges of 10–20 kDa, 25–35 kDa, and 45–75 kDa, which were consistent with the bands of the standard.
[0072] The extract of Artemisia annua pollen allergen showed protein bands in the ranges of 10–15 kDa, 25–40 kDa, and 65–75 kDa, which were consistent with the bands of the standard.
[0073] (2) Identification of allergens from four Artemisia species using Western blotting method
[0074] Reduced SDS-PAG electrophoresis was performed using a separating gel concentration of 4%–12% on a 0.2 μm PVDF Immobilon R-PSQ transfer membrane. The primary antibody (a mixture of serum from patients with Artemisia pollen allergy) was diluted 1:3. Hybridization was carried out at room temperature for 2 hours, followed by overnight hybridization at 4°C. The membrane was washed three times with 1×PBST for 10 min each time. The secondary antibody (mouse monoclonal antibody against human IgE Fc HRP Abcam, ab99806) was diluted 1:1000 and hybridized at room temperature for 2 hours, followed by three washes with 1×PBST for 10 min each time. ECL developing solutions A and B (Immobilon, WBKLS0500) were mixed 1:1 and exposed for color development.
[0075] The experimental results are shown in Figure 2. The results showed that allergens in the pollen of Artemisia annua, Artemisia argyi, Artemisia argyi, and Artemisia sphaeroides were positive.
[0076] (3) Determination of the biopotency of pollen from four Artemisia species
[0077] When the allergen extract contained therapeutically or diagnostically effective amounts of pollen allergens from *Artemisia annua*, *Artemisia argyi*, *Artemisia argyi*, or *Artemisia scoparia*, a competitive ELISA method was used. The corresponding pollen allergen was used as the coating antigen. The primary antibody was a mixed serum sample from patients with *Artemisia* pollen allergy, and the secondary antibody was a biotin-labeled goat anti-human IgE antibody (Seracare, KPL16-10-04). The sample was then incubated with horseradish enzyme-labeled streptavidin (ZSGB-BIO, ZB-2404), and TMB chromogenic solution (Thermo, 34028) and 2 mol / L sulfuric acid were used as the chromogenic and stop solutions. The determined biotiters ranged from 50,000 to 200,000 AU / mL.
[0078] Example 3: Preparation of sublingual tablets containing four mixed Artemisia pollen allergens
[0079] 3.1 Preparation of fish gelatin excipients
[0080] Deep-sea cold-water fish gelatin A1, cold-water fish gelatin A2, and warm-water fish gelatin B1 were prepared using pollock skin, rainbow trout skin, and tilapia skin, respectively, using the following preparation methods. Thawed fish skin was cleaned and excess water was wiped away. An appropriate amount of fish skin was weighed and added to 0.1 mol / L NaOH solution at a weight-to-volume ratio (w / v) of 1:10, and soaked for 2 hours at room temperature with stirring. After soaking, the skin was rinsed with distilled water until the pH reached 7, and then dried with absorbent paper. Fish skin was then soaked in 0.05 M acetic acid solution at a weight-to-volume ratio (w / v) of 1:10 for 5 hours, followed by rinsing with distilled water until neutral. Fish skin was then soaked in distilled water at a weight-to-volume ratio (w / v) of 1:10 at 55°C with stirring at 120 rpm / min for 6 hours. After extraction, impurities were removed by filtration, and the gelatin was dried to obtain the final product. Warm-water fish gelatin B2 differs from warm-water fish gelatin B1 only in that it is prepared using tilapia scales.
[0081] 3.2 Reconstitution of extracts from four Artemisia spp. pollen allergens
[0082] The allergen extracts of Artemisia annua, Artemisia argyi, Artemisia argyi, and Artemisia argyi pollen were dissolved in purified water and mixed in a ratio of 1:1:1:1 to prepare a mixed Artemisia annua, Artemisia argyi, and Artemisia argyi pollen allergen stock solution with a total protein content of 1.00 mg / mL.
[0083] 3.3 Preparation of lyophilized tablet semi-finished product
[0084] Mix the ingredients according to the formulations in Tables 3.2 to 3.12. First, weigh out each excipient (gelatin and mannitol) and mix them in a 40°C water bath until the excipients are completely dissolved and there is no clumping or sedimentation. Adjust the pH to 6.8–6.9 and allow it to cool to room temperature before use. Add the mixed Artemisia pollen allergen stock solution to the excipient solution, mix thoroughly, and then filter sterilely through a 0.22 μm polyethersulfone membrane. The resulting mixed Artemisia pollen allergen sublingual lyophilized tablet semi-finished product is used as the composition for lyophilization.
[0085] 3.4 Sample loading, freeze drying, and film packaging
[0086] Add 400 μL of the semi-finished product solution to each aluminum foil blister pack. Pre-freeze the blister packs at the appropriate temperature for the corresponding time. Perform freeze-drying according to the freeze-drying parameters in Table 3.1. After freeze-drying, cover with an aluminum foil composite film at a relative humidity of 5%–40%, cut, and package.
[0087] Table 3.1 Freeze-drying parameter settings
[0088] In the following examples, A1 represents deep-sea cold-water fish gelatin, A2 represents cold-water fish gelatin, B1 represents warm-water fish gelatin, B2 represents warm-water fish gelatin, C represents porcine gelatin (purchased from Sigma-Aldrich), and D represents bovine bone gelatin (purchased from Baotou Dongbao Biotechnology Co., Ltd.). Mannitol was purchased from Shijiazhuang Huaxu Pharmaceutical Co., Ltd., and sodium hydroxide was purchased from Sichuan Jinshan Pharmaceutical Co., Ltd. The amounts of gelatin and mannitol are shown as (m / v)% and the amount of mixed Artemisia pollen allergens is calculated based on the allergen concentrations of the four Artemisia pollen allergens, for example, 0.5 mg / mL is the allergen concentration in the lyophilized composition. Figure 3 shows front and back photographs of the finished mixed Artemisia pollen sublingual tablets from group 48.
[0089] Table 3.2
[0090] Table 3.3
[0091] Table 3.4
[0092] Table 3.5
[0093] Table 3.6
[0094] Table 3.7
[0095] Table 3.8
[0096] Table 3.9
[0097] Table 3.10
[0098] Table 3.11
[0099] Table 3.12
[0100] Example 4. Evaluation Results
[0101] 4.1 Appearance and characteristics score
[0102] Tablet appearance scores are shown in Table 4.1. Each evaluation index has a full score of 10 points, of which 8-10 points is excellent and below 5 points is unqualified. The total score for tablet appearance is 50 points. If a single evaluation index is unqualified, the overall tablet appearance score is also unqualified.
[0103] Table 4.1 Tablet Appearance Rating Table
[0104] Table 4.2
[0105] Table 4.3
[0106] Table 4.4
[0107] The experimental results in Tables 4.2-4.4 show that tablets made from deep-sea cold-water fish gelatin have better appearance and disintegration properties than those made from cold-water fish gelatin, warm-water fish gelatin, porcine gelatin, and bovine bone gelatin. Based on the appearance of each group of tablets, the sublimation drying temperature of -15℃ is better than that of -20℃ and -25℃. Furthermore, as the sublimation drying temperature decreases, the excipient precipitation in the freeze-dried tablets becomes more severe, thus affecting the tablet's appearance and disintegration.
[0108] Table 4.5
[0109] Table 4.6
[0110] The experimental results in Tables 4.2, 4.5, and 4.6 show that the precipitation phenomenon of excipients in all tablet groups was alleviated with the increase of sublimation drying time. Tablets made from deep-sea cold-water fish gelatin, under a sublimation drying time of 5 hours, exhibited better appearance and disintegration properties than those made from cold-water fish gelatin, warm-water fish gelatin, porcine gelatin, and bovine bone gelatin. Therefore, a sublimation drying time of 5 hours is preferred, and deep-sea cold-water fish gelatin is the preferred excipient.
[0111] Table 4.7
[0112] Table 4.8
[0113] The experimental results in Tables 4.5, 4.7, and 4.8 show that tablets prepared at higher pre-freezing temperatures have a rougher appearance, while tablets prepared at excessively low pre-freezing temperatures will produce a large amount of gelatin precipitation, affecting their appearance and disintegration. Therefore, the preferred pre-freezing temperature is -60℃ to -120℃, and more preferably -100℃.
[0114] Table 4.9
[0115] As can be seen from the experimental results in Table 4.9, pre-freezing at -100℃ for 2 minutes did not cause the tablet to freeze completely inside, so it had a certain impact on the appearance of the finished tablet. The finished tablets made by pre-freezing for 3 minutes, 5 minutes, 10 minutes and 30 minutes had similar appearance characteristics. Therefore, the preferred pre-freezing time is 2.5 to 30 minutes, and more preferably 5 to 10 minutes.
[0116] Table 4.10
[0117] Table 4.11
[0118] The experimental results in Tables 4.10 and 4.11 show that using 4% deep-sea cold-water fish gelatin and 6% mannitol resulted in the best appearance and disintegration properties of the finished tablets.
[0119] Table 4.12
[0120] As shown in Table 4.12, the tablet preparation method and excipient ratio provided in this disclosure are suitable for preparing mixed Artemisia pollen with an allergen content of 5-800 μg / tablet and a biopotency of 20,000-80,000 AU / tablet. There are no significant differences in appearance and disintegration among the groups. As the active ingredient increases, the tablet color becomes darker.
[0121] Example 5: Preparation of sublingual tablets containing pollen allergens from single-species Artemisia annua, Artemisia argyi, Artemisia vulgaris, and Artemisia serrata.
[0122] The method for preparing sublingual tablets containing mixed Artemisia pollen allergens described in this disclosure is also applicable to the preparation of sublingual tablets containing single-variety Artemisia pollen allergens.
[0123] Artemisia pollen allergen sublingual tablets were prepared according to the method in Group 48 of Example 3, except that the mixed Artemisia pollen allergen was replaced with one of the four pollen allergens.
[0124] Table 5.1 Tablet Prescription Table
[0125] The properties and dosage of gelatin were evaluated based on the appearance, hardness, blister adhesion, and disintegration time of the tablets. The experimental results are shown in Table 5.2.
[0126] Table 5.2 Tablet Appearance
[0127] As can be seen from the experimental results in Table 5.2, the method for preparing sublingual tablets of mixed Artemisia pollen provided in this disclosure is also applicable to the preparation of sublingual tablets of single-variety pollen allergens such as Artemisia argyi, Artemisia annua, Artemisia argyi, and Artemisia serrata, and the finished sublingual tablets have the same properties as the sublingual tablets of mixed Artemisia pollen allergens.
[0128] Example 6: Preparation of sublingual tablets containing ragweed, hops, juniper, and birch pollen allergens
[0129] The method for preparing sublingual tablets containing mixed Artemisia pollen allergens described in this disclosure is also applicable to the preparation of sublingual tablets containing other grass pollen and tree pollen allergens.
[0130] Pollen allergen sublingual tablets were prepared according to the method in Group 48 of Example 3, except that the mixed Artemisia pollen allergen was replaced with pollen allergens of other species.
[0131] Table 6.1 Tablet Prescription Table
[0132] The properties and dosage of gelatin were evaluated based on the appearance, hardness, blister adhesion, and disintegration time of the tablets. The experimental results are shown in Table 6.2.
[0133] Table 6.2 Tablet Appearance
[0134] As can be seen from the experimental results in Table 6.2, the method for preparing sublingual tablets of mixed Artemisia pollen provided in this disclosure is also applicable to the preparation of sublingual tablets of other grass pollen and tree pollen allergens, and the finished sublingual tablets have the same properties as the sublingual tablets of mixed Artemisia pollen allergens.
[0135] Example 7: Quality Control of Mixed Artemisia Pollen Sublingual Tablets
[0136] The sublingual tablets containing mixed Artemisia pollen from group 48 were subjected to relevant quality checks, and the results are as follows:
[0137] Table 7.1 Quality Inspection Results of Finished Tablets
[0138] Example 8: Comparative Detection of Biological Activities of Sublingual Pieces of Mixed Artemisia Pollen Prepared with Different Freeze-Drying Curves
[0139] Sublingual tablets from groups 1, 7, and 13 were selected and subjected to competitive ELISA. A mixed Artemisia pollen allergen was used as the coating antigen. The primary antibody was a mixture of serum from patients with Artemisia pollen allergy, and the secondary antibody was a biotin-labeled goat anti-human IgE antibody (Seracare, KPL16-10-04). The tablets were then incubated with horseradish enzyme-labeled streptavidin (ZSGB-BIO, ZB-2404). TMB chromogenic solution (Thermo, 34028) and 2 mol / L sulfuric acid were used as the chromogenic and reaction termination solutions. The total allergen activity of the three groups of tablets ranged from 50% to 200%, with no significant difference in biological activity.
[0140] Example 9: Comparative Experiment of Mixed Artemisia pollen Sublingual Tablets and Commercially Available Allergen Sublingual Tablets
[0141] Sublingual tablets from group 48 were selected and compared with commercially available and related research and development tablets in terms of appearance, disintegration time, etc. The results are shown in Table 9.1. Among them, group 48 consists of sublingual tablets of mixed Artemisia pollen prepared by the preparation method provided in this disclosure (group 48), a-d are orally disintegrating tablets commercially available in China for the treatment or relief of allergic symptoms, and e is a sublingual tablet for house dust mite allergens.
[0142] Table 9.1
[0143] Example 10 Animal safety experiment of mixed Artemisia pollen sublingual tablets
[0144] Based on the "Technical Guidelines for Single-Dose Toxicity Studies of Drugs" (2014) issued by the China Food and Drug Administration, ICR mice were administered Artemisia pollen allergen sublingual tablets in group 48 via a single sublingual administration within 24 hours. The dosage design is shown in Table 10.1. The poisoning and mortality were observed.
[0145] Table 10.1 Dosage Design for Single-Dose Toxicity Studies
[0146] The experimental results showed that, under the conditions of this experiment, the maximum tolerated dose (MTD) of the sublingual tablets for Artemisia pollen allergen in ICR mice was greater than 1260 mg / kg / day. After administration, the mice showed no abnormalities in any of their physical signs and there were no signs of poisoning or death.
[0147] Example 11 Animal efficacy study of mixed Artemisia pollen sublingual tablets
[0148] (1) Construction of an animal model of sensitization by Artemisia pollen
[0149] BALB / c mice were intraperitoneally injected with 200 μL of physiological saline (normal group) and Artemisia pollen sensitization solution (modeling group) on days 1, 6, 11 and 16, respectively; and nebulized with physiological saline (normal group) and Artemisia pollen allergen extract (modeling group) from days 21 to 27 for 30 min each day for 7 consecutive days.
[0150] The 200 μL Artemisia pollen sensitization solution contained equal weights of four Artemisia pollen allergen extracts prepared in Example 1 (total allergen content of 1 μg / μL) and aluminum hydroxide adjuvant (1.5 mg); the Artemisia pollen allergen infusion was a solution of equal weights of the four Artemisia pollen allergen extracts prepared in Example 1 (total allergen content of 1 μg / μL), and the same applies below.
[0151] (2) Immunotherapy and allergic stimulation with mixed Artemisia pollen sublingual tablets
[0152] From day 35 to day 48, mice in the immunotherapy group (N=7) were administered one sublingual tablet of group 48 per day, while mice in the normal group (N=5) and the model control group (N=8) were administered physiological saline sublingually once a day for 14 consecutive days. From day 49 to day 55, mice in the normal group and the model control group (N=8) were administered physiological saline (nebulized) and 1 μg / μl Artemisia pollen allergen extract (nebulized) for 30 min per day for 7 consecutive days.
[0153] (3) Evaluation of sublingual immunotherapy with mixed Artemisia pollen tablets
[0154] On day 55, after nebulized administration to mice, allergic symptoms were observed in BALB / c mice. Sneezing and nose scratching were observed and recorded within 20 minutes. The experimental results are shown in Table 11.1. After the allergic symptom observation was completed, the mice were dissected, lung tissue was taken, and pathological sections (HE staining) were prepared. The histopathological examination results are shown in Figure 5.
[0155] Table 11.1 Results of Symptom Observation for Sublingual Tablet Immunotherapy with Mixed Artemisia Pollen
[0156] The observation results in Table 11.1 show that the allergic symptoms of Artemisia pollen-sensitized mice treated with sublingual tablets in group 48 were significantly better than those in the model control group (P<0.05), demonstrating a good therapeutic effect on allergic symptoms.
[0157] Histopathological examination results are shown in Figure 5. The results showed that in the normal group mice, the lung tissue structure was clear, the airway walls were thin and uniform, the bronchial smooth muscle thickness was normal, and there was almost no inflammatory cell infiltration. In the model control group, obvious inflammatory cell infiltration and significant airway wall thickening were observed. These changes suggest severe airway inflammation and structural remodeling in the asthma model. Compared with the model control group, the immunotherapy group had clearer lung tissue structure, thinner airway walls, and less obvious inflammatory cell infiltration.
[0158] Example 12 Sublingual administration test of mixed Artemisia pollen sublingual tablets
[0159] Ten healthy subjects without a history of Artemisia pollen allergy were selected for a sublingual administration test of mixed Artemisia pollen sublingual tablets (prepared under cGMP conditions using the formulation and process of Group 48). All participants signed informed consent forms, and the test was conducted under appropriate protective measures.
[0160] Table 12.1 Summary of sublingual administration test results for mixed Artemisia pollen sublingual tablets
[0161] The test results in Table 12.1 show that the sublingual tablets are slightly sweet and have no off-taste after being taken orally. They disintegrate rapidly after ingestion, dissolving completely within 20–35 seconds. Two subjects experienced mild local adverse reactions, which resolved spontaneously within 15 minutes. No serious adverse reactions occurred in any subject, and no delayed onset or recurrence of adverse reactions was observed in any subject within 24 hours.
[0162] By incorporating references
[0163] The full contents of every patent and scientific document mentioned in this article are incorporated herein by reference for all purposes.
[0164] Equivalence
[0165] This disclosure may be embodied in other specific ways without departing from its spirit or essential characteristics. Therefore, the above embodiments should be considered illustrative in all cases and not as limiting of the invention described herein. Consequently, the scope of this disclosure is defined by the appended claims rather than by the foregoing description and is intended to be encompassed therein by all variations within the equivalent meaning and scope of the claims.
Claims
1. A process for the preparation of a sublingual tablet, characterized in that, The sublingual tablets contain pollen allergen, gelatin, and mannitol, and the preparation method includes pre-freezing, sublimation drying, and desorption drying of the lyophilization composition containing pollen allergen, gelatin, and mannitol in sequence. In this composition, the amount of gelatin used is 3% to 10% (w / v) and the amount of mannitol used is 3% to 10% (w / v) relative to the freeze-drying composition. The pre-freezing temperature is -60℃ to -120℃, and the time is 2 to 30 minutes; the sublimation drying temperature is -5℃ to -30℃, and the time is 3 to 7 hours.
2. The production method according to claim 1, wherein The pollen allergens are one or more pollen allergens from weed pollen, pasture pollen and tree pollen; Preferably, the weed pollen includes Artemisia pollen, Kochia pollen, Ragweed pollen, Humulus pollen, and Xanthium pollen; and / or the pasture pollen includes Foxtail grass pollen, Tigrass pollen, and Bermuda grass pollen; and / or the tree pollen includes Juniperus chinensis pollen, Ash pollen, Birch pollen, Platanus pollen, Juniperus chinensis pollen, Populus tomentosa pollen, Cryptomeria japonica pollen, Elm pollen, and Willow pollen; Preferably, the pollen allergen is an Artemisia pollen allergen; more preferably, the Artemisia pollen allergen comprises one or more Artemisia pollen allergens selected from Artemisia sieversiana, Artemisia annua, Artemisia vulgaris, Artemisia desertorum, Artemisia ordosica, and Artemisia stelleriana; even more preferably, the Artemisia pollen allergen comprises one or more Artemisia pollen allergens selected from Artemisia sieversiana, Artemisia annua, Artemisia vulgaris, and Artemisia desertorum; Preferably, in the Artemisia pollen allergens, the protein content ratio of Artemisia macrocarpa pollen allergen, Artemisia annua pollen allergen, Artemisia argyi pollen allergen, and Artemisia sphaeroides pollen allergen is 1:(0.1-10):(0.1-10):(0.1-10), more preferably 1:(0.5-2):(0.5-2):(0.5-2), and even more preferably 1:1:1:
1.
3. The production method according to claim 1 or 2, wherein The gelatin is cold-water fish gelatin, preferably deep-sea cold-water fish gelatin, such as one or more of salmon gelatin, cod gelatin, yellow croaker gelatin and tuna gelatin.
4. The production process according to any one of claims 1 to 3, wherein, The amount of gelatin used relative to the freeze-drying composition is 4% to 7% (w / v); and / or the amount of mannitol used is 5% to 7% (w / v); Preferably, the pollen allergen content is 0.01–2.0 mg / mL, more preferably 0.1–1 mg / mL, relative to the freeze-drying composition; Preferably, the biopotency of the pollen allergen is 50,000 to 200,000 AU / mL.
5. The production process according to any one of claims 1 to 4, wherein, The preparation method includes: adjusting the pH of the lyophilization composition to 6.5-7.5, preferably 6.5-7.2, and more preferably 6.8-6.9 before pre-freezing; Preferably, the pH of the lyophilization composition is adjusted using sodium hydroxide or a solution thereof.
6. The production process according to any one of claims 1 to 5, wherein, The pre-freezing temperature is -80℃ to -120℃; the time is 2.5 to 30 minutes.
7. The production process according to any one of claims 1 to 6, wherein The sublimation drying temperature is -15℃ to -25℃; the time is 5 to 7 hours. Preferably, the temperature for the analytical drying is 20℃~30℃, more preferably 25℃; and the time is 1~3h, more preferably 2.5h.
8. A sublingual tablet prepared by any one of claims 1-7.
9. The sublingual tablet according to claim 8, wherein, The sublingual tablets are in single-dose form, and the total pollen allergen protein content in the sublingual tablets is 4-800 μg / tablet, preferably 40-400 μg / tablet; preferably, the pollen allergen biopotency in the sublingual tablets is 20,000-80,000 AU / tablet; preferably, the filling volume of the sublingual tablets before lyophilization is 200-800 μL / tablet, preferably 300-600 μL / tablet, more preferably 400 μL / tablet; Preferably, the sublingual tablet is a fast-disintegrating sublingual tablet; Preferably, the disintegration time of the sublingual tablet is within 20 seconds, more preferably within 10 seconds, and even more preferably within 5 seconds.
10. Use of the sublingual tablet of claim 8 or 9 in the preparation of a medicament or reagent for treating and / or preventing allergic rhinitis, allergic conjunctivitis or allergic asthma caused by pollen, or for diagnosing allergies.
11. A method for treating and / or preventing allergic rhinitis, allergic conjunctivitis, or allergic asthma caused by pollen, or for diagnosing allergies, comprising administering an effective amount of the sublingual tablet of claim 8 or 9 to a subject in need.
